Objetivo
Four to five million people in Europe and about 80 million worldwide suffer from type 1 diabetes (insulin-dependent), characterized by a deficiency in insulin secretion resulting in hyperglycaemia responsible for debilitating long-term complications (coronary diseases, acquired blindness, chronic renal failures). Recently developed immunosuppressive protocols improved the success of humanallogenic pancreatic islets transplantation. However, such transplantation has severe limitations: the number of available donors and the potential toxicity of the immunosuppressive treatments. To avoidimmunosupression, islets could be encapsulated to protect them from the attack of the immune system and thus from rejection.
This project intends to develop, improve and validate an efficient reliablebioartificial pancreas for human application. To achieve this ambitious goal, various disciplines reintegrated in a true task force of basic and clinical researchers with leading expertise in experimental diabetes and advanced modern material technologies to develop an effective approach for the treatment of type 1 diabetes. The proposed approach takes into account the far-reaching advances in the modernnanosize technology, which are of utmost importance for the success of this challenge. To canny out the project to a successful achievement, the consortium gathers a multidisciplinary group of leading European scientists with complementary competencies, spending from biomaterials to tissue engineering, and high-tech Sees. This transactional approach provides convincing solutions to bypass the limitations of traditional treatments of this disease. That proposal fits perfectly within the scope of Priority Nan technologies and Nan sciences, 3.4.1 in particular Biotechnologies-biotechnologies, 3.4.1.2.Furthermore the proposal addressed also the 3.4.1.5 Application in areas such as health and medical systems, chemistry, energy, optics, food and environment.
Ámbito científico
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinetransplantation
Palabras clave
Tema(s)
Convocatoria de propuestas
FP6-2002-NMP-1
Consulte otros proyectos de esta convocatoria
Régimen de financiación
STREP - Specific Targeted Research ProjectCoordinador
STRASBOURG
Francia